Supernus Pharmaceuticals (FRA:S49) Institutional Ownership : 80.30% (As of May. 15, 2024)

View and export this data going back to 2013. Start your Free Trial

What is Supernus Pharmaceuticals Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Supernus Pharmaceuticals's institutional ownership is 80.30%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Supernus Pharmaceuticals's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Supernus Pharmaceuticals's Float Percentage Of Total Shares Outstanding is 66.11%.

Supernus Pharmaceuticals Institutional Ownership Historical Data

The historical data trend for Supernus Pharmaceuticals's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Institutional Ownership Chart

Supernus Pharmaceuticals Historical Data

The historical data trend for Supernus Pharmaceuticals can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	81.46	81.67	82.27	81.22	78.43	78.79	80.00	80.25	80.46	80.30

Supernus Pharmaceuticals Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Supernus Pharmaceuticals (FRA:S49) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (FRA:S49) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

SUPN:USA S49:Germany

Address

9715 Key West Avenue, Rockville, MD, USA, 20850

Website

https://www.supernus.com

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals (FRA:S49) Headlines

No Headlines